Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
Summary
In a multicentre phase 2b RCT (n=404 treated), once-daily oral elecoglipron produced clinically meaningful glycaemic reductions with a safety/tolerability profile consistent with GLP-1 receptor agonists. These findings support advancement to phase 3 for type 2 diabetes treatment.
Key Findings
- Randomised, double-blind, placebo-controlled phase 2b trial across nine countries; 404 participants received study drug.
- Once-daily oral elecoglipron achieved glycaemic reductions versus placebo.
- Safety and tolerability were consistent with the GLP-1RA class.
Clinical Implications
If confirmed in phase 3, elecoglipron could broaden GLP-1RA use to patients averse to injections, simplifying treatment logistics without food/fluid restrictions.
Why It Matters
Demonstrates efficacy of a once-daily oral small-molecule GLP-1RA—potentially transforming access and adherence compared with injectables or peptide-based oral formulations.
Limitations
- Phase 2b duration and endpoints limit long-term efficacy/safety inference
- Abstract excerpt lacks detailed HbA1c and dose-response data in this summary
Future Directions
Conduct phase 3 trials to confirm durability, cardiovascular/renal outcomes, and head-to-head comparisons with injectable GLP-1RAs and SGLT2 inhibitors.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomised, double-blind, placebo-controlled phase 2b clinical trial
- Study Design
- OTHER